Immunovant, Inc. (IMVT)
NASDAQ$14.72
Market Cap
$2.5B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
1 of 883
Rank in Industry
1 of 510
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
| $259M | ||
| $79M | ||
| $76M | ||
| $60M | ||
| $57M | ||
| $50M |
IMVT Insider Trading Activity
IMVT Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $336,900,200 | 1 | 2 |
Sells | $7,014,941 | 52 | 98 |
Related Transactions
| Roivant Sciences Ltd. | 1 | $336.9M | 0 | $0 | $336.9M | |
| Hughes Douglas J. | director | 0 | $0 | 1 | $154,830 | $-154,830 |
| Fromkin Andrew J. | director | 0 | $0 | 1 | $156,769 | $-156,769 |
| Pande Atul | director | 0 | $0 | 1 | $221,185 | $-221,185 |
| Stout Jay S | Chief Technology Officer | 0 | $0 | 4 | $239,252 | $-239,252 |
| Geffner Michael | Chief Medical Officer | 0 | $0 | 4 | $287,530 | $-287,530 |
| Butchko Julia G. | Chief Development Officer | 0 | $0 | 4 | $320,690 | $-320,690 |
| Macias William L. | Chief Medical Officer | 0 | $0 | 7 | $559,863 | $-559,863 |
| Levine Mark S. | Chief Legal Officer | 0 | $0 | 7 | $690,952 | $-690,952 |
| Barnett Eva Renee | Chief Financial Officer | 0 | $0 | 11 | $1.08M | $-1.08M |
| Salzmann Peter | Chief Executive Officer | 0 | $0 | 12 | $3.31M | $-3.31M |
About Immunovant, Inc.
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is …
Insider Activity of Immunovant, Inc.
Over the last 12 months, insiders at Immunovant, Inc. have bought $336.9M and sold $7.01M worth of Immunovant, Inc. stock.
On average, over the past 5 years, insiders at Immunovant, Inc. have bought $85.7M and sold $6.5M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Roivant Sciences Ltd. () — $336.9M.
The last purchase of 16,845,010 shares for transaction amount of $336.9M was made by Roivant Sciences Ltd. () on 2025‑01‑13.
List of Insider Buy and Sell Transactions, Immunovant, Inc.
| 2025-04-23 | Sale | Geffner Michael | Chief Medical Officer | 2,349 0.0014% | $14.79 | $34,742 | +0.02% | |
| 2025-04-23 | Sale | Stout Jay S | Chief Technology Officer | 1,925 0.0012% | $14.79 | $28,471 | +0.02% | |
| 2025-04-16 | Sale | Salzmann Peter | Chief Executive Officer | 8,321 0.0051% | $14.89 | $123,900 | -0.99% | |
| 2025-04-16 | Sale | Barnett Eva Renee | Chief Financial Officer | 2,993 0.0018% | $14.89 | $44,566 | -0.99% | |
| 2025-04-09 | Sale | Salzmann Peter | Chief Executive Officer | 28,094 0.0149% | $12.99 | $364,941 | +14.94% | |
| 2025-03-07 | Sale | Fromkin Andrew J. | director | 8,000 0.0047% | $19.60 | $156,769 | -20.15% | |
| 2025-02-19 | Sale | Salzmann Peter | Chief Executive Officer | 15,439 0.0091% | $20.86 | $322,058 | -12.58% | |
| 2025-02-19 | Sale | Macias William L. | Chief Medical Officer | 2,055 0.0012% | $20.86 | $42,867 | -12.58% | |
| 2025-02-19 | Sale | Barnett Eva Renee | Chief Financial Officer | 2,814 0.0017% | $20.86 | $58,700 | -12.58% | |
| 2025-01-22 | Sale | Stout Jay S | Chief Technology Officer | 2,195 0.0015% | $23.59 | $51,780 | -16.01% | |
| 2025-01-22 | Sale | Geffner Michael | Chief Medical Officer | 2,657 0.0018% | $23.59 | $62,679 | -16.01% | |
| 2025-01-15 | Sale | Salzmann Peter | Chief Executive Officer | 8,767 0.0059% | $23.83 | $208,900 | -20.00% | |
| 2025-01-15 | Sale | Macias William L. | Chief Medical Officer | 2,383 0.0016% | $23.83 | $56,782 | -20.00% | |
| 2025-01-15 | Sale | Barnett Eva Renee | Chief Financial Officer | 2,298 0.0016% | $23.83 | $54,757 | -20.00% | |
| 2025-01-13 | Roivant Sciences Ltd. | 16.85M 10.1065% | $20.00 | $336.9M | -13.80% | |||
| 2025-01-08 | Sale | Salzmann Peter | Chief Executive Officer | 5,105 0.0035% | $24.10 | $123,031 | -16.89% | |
| 2025-01-08 | Sale | Barnett Eva Renee | Chief Financial Officer | 4,105 0.0028% | $24.10 | $98,931 | -16.89% | |
| 2024-12-02 | Sale | Hughes Douglas J. | director | 5,425 0.0037% | $28.54 | $154,830 | -29.07% | |
| 2024-12-02 | Sale | Pande Atul | director | 7,750 0.0052% | $28.54 | $221,185 | -29.07% | |
| 2024-11-20 | Sale | Salzmann Peter | Chief Executive Officer | 16,692 0.0111% | $25.45 | $424,811 | -20.10% |
Total: 166
*Gray background shows transactions not older than one year
Insider Historical Profitability
85.24%
| Roivant Sciences Ltd. | 96650341 56.8997% | $1.42B | 6 | 0 | +30.04% | |
| Butchko Julia G. | Chief Development Officer | 440959 0.2596% | $6.49M | 1 | 22 | <0.0001% |
| Hughes Douglas J. | director | 119585 0.0704% | $1.76M | 1 | 1 | <0.0001% |
| Fromkin Andrew J. | director | 91913 0.0541% | $1.35M | 1 | 2 | <0.0001% |
| Pande Atul | director | 86663 0.051% | $1.28M | 2 | 2 | +99.21% |
| WONG RODERICK | Chief Executive Officer | 902498 0.5313% | $13.28M | 22 | 0 | +118.39% |
| MIGAUSKY GEORGE V | director | 109808 0.0646% | $1.62M | 1 | 1 | <0.0001% |
*Gray background shows insiders who have made transactions during last year
Historical Insider Profitability vs. Competitors
$66,492,695 | 135 | 27.65% | $2.08B | |
$193,151,375 | 134 | 8.18% | $2.26B | |
$11,588,217 | 69 | 42.07% | $2.86B | |
Immunovant, Inc. (IMVT) | $140,165,669 | 33 | 85.24% | $2.5B |
$1,275,975,557 | 32 | 19.44% | $2.46B |
IMVT Institutional Investors: Active Positions
| Increased Positions | 110 | +53.66% | 12M | +14.87% |
| Decreased Positions | 93 | -45.37% | 10M | -12.43% |
| New Positions | 41 | New | 2M | New |
| Sold Out Positions | 30 | Sold Out | 4M | Sold Out |
| Total Postitions | 222 | +8.29% | 81M | +2.44% |
IMVT Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Fmr Llc | $198,433.00 | 7.71% | 13.1M | +560,344 | +4.47% | 2024-12-31 |
| Vanguard Group Inc | $101,193.00 | 3.93% | 6.68M | +20,614 | +0.31% | 2024-12-31 |
| Deep Track Capital, Lp | $90,900.00 | 3.53% | 6M | +2M | +38.01% | 2024-12-31 |
| Blackrock, Inc. | $77,918.00 | 3.03% | 5.14M | +89,921 | +1.78% | 2024-12-31 |
| T. Rowe Price Investment Management, Inc. | $77,526.00 | 3.01% | 5.12M | +2M | +53.62% | 2024-12-31 |
| Armistice Capital, Llc | $58,639.00 | 2.28% | 3.87M | +322,586 | +9.09% | 2024-12-31 |
| State Street Corp | $40,867.00 | 1.59% | 2.7M | -324,820 | -10.75% | 2024-12-31 |
| Alpine Global Management, Llc | $32,707.00 | 1.27% | 2.16M | +276,200 | +14.67% | 2024-12-31 |
| Perceptive Advisors Llc | $32,409.00 | 1.26% | 2.14M | -239,563 | -10.07% | 2024-12-31 |
| Baker Bros. Advisors Lp | $25,874.00 | 1.01% | 1.71M | +482,471 | +39.37% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Price to Earnings
Price/Earnings to Growth
Price to Sales
Price to Book
Price/Free Cash Flow
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.